- Home
- XOMAP vs KRMD Comparison
XOMAP vs KRMD Comparison
Compare XOMAP & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- KRMD
- Stock Information
- Founded
- XOMAP N/A
- KRMD 1980
- Country
- XOMAP United States
- KRMD United States
- Employees
- XOMAP 13
- KRMD N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- KRMD Medical/Dental Instruments
- Sector
- XOMAP Health Care
- KRMD Health Care
- Exchange
- XOMAP Nasdaq
- KRMD Nasdaq
- Market Cap
- XOMAP N/A
- KRMD N/A
- IPO Year
- XOMAP N/A
- KRMD N/A
- Fundamental
- Price
- XOMAP $25.93
- KRMD $2.51
- Analyst Decision
- XOMAP
- KRMD Strong Buy
- Analyst Count
- XOMAP 0
- KRMD 4
- Target Price
- XOMAP N/A
- KRMD $4.88
- AVG Volume (30 Days)
- XOMAP N/A
- KRMD 158.7K
- Earning Date
- XOMAP N/A
- KRMD 03-12-2025
- Dividend Yield
- XOMAP N/A
- KRMD N/A
- EPS Growth
- XOMAP N/A
- KRMD N/A
- EPS
- XOMAP N/A
- KRMD N/A
- Revenue
- XOMAP N/A
- KRMD $33,646,463.00
- Revenue This Year
- XOMAP N/A
- KRMD $16.39
- Revenue Next Year
- XOMAP N/A
- KRMD $16.27
- P/E Ratio
- XOMAP N/A
- KRMD N/A
- Revenue Growth
- XOMAP N/A
- KRMD 17.98
- 52 Week Low
- XOMAP N/A
- KRMD $2.05
- 52 Week High
- XOMAP N/A
- KRMD $5.05
- Technical
- Relative Strength Index (RSI)
- XOMAP 58.85
- KRMD 27.54
- Support Level
- XOMAP $25.73
- KRMD $2.50
- Resistance Level
- XOMAP $25.93
- KRMD $2.66
- Average True Range (ATR)
- XOMAP 0.09
- KRMD 0.17
- MACD
- XOMAP 0.03
- KRMD 0.00
- Stochastic Oscillator
- XOMAP 93.11
- KRMD 4.48
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.